StockData
Arrowhead Pharmaceuticals, Inc. logo

Arrowhead Pharmaceuticals, Inc. (ARWR) stock

ARWRNasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Nov 12, 2026Score 5/3035% above fair value
$42.99−1.22 (-2.76%)

Close on Nov 17, 2026Market cap $6.07BP/E –Yield –

Arrowhead Pharmaceuticals cash

Cash and short-term investments held at the end of each period.

Arrowhead Pharmaceuticals's cash was $1.60B at Jun 30, 2026. For fiscal 2025 it was $919.37M, up 35.0% from the year before. Over ten years it grew 27.5% a year on average. The highest annual figure on record is $919.37M in fiscal 2025.

Annual cash

PeriodPeriod endValueChange
FY2025Sep 30, 2025$919.37M+35.0%
FY2024Sep 30, 2024$680.96M+68.7%
FY2023Sep 30, 2023$403.63M+273.7%
FY2022Sep 30, 2022$108.01M-65.3%
FY2021Sep 30, 2021$311.16M+36.1%
FY2020Sep 30, 2020$228.60M+3.1%
FY2019Sep 30, 2019$221.80M+636.1%
FY2018Sep 30, 2018$30.13M+21.3%
FY2017Sep 30, 2017$24.84M-70.9%
FY2016Sep 30, 2016$85.37M+5.1%
FY2015Sep 30, 2015$81.21M-47.3%
FY2014Sep 30, 2014$154.16M+447.8%
FY2013Sep 30, 2013$28.14M+707.9%
FY2012Sep 30, 2012$3.48M-57.2%
FY2011Sep 30, 2011$8.14M+18.9%
FY2010Sep 30, 2010$6.85M+238.9%
FY2009Sep 30, 2009$2.02M–

Quarterly cash

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q3 FY2026CQ2 2026Jun 30, 2026$1.60B+77.9%
Q2 FY2026CQ1 2026Mar 31, 2026$1.78B+62.6%
Q1 FY2026CQ4 2025Dec 31, 2025$916.61M+65.8%
Q4 FY2025CQ3 2025Sep 30, 2025$919.37M+35.0%
Q3 FY2025CQ2 2025Jun 30, 2025$900.37M+106.2%
Q2 FY2025CQ1 2025Mar 31, 2025$1.10B+109.8%
Q1 FY2025CQ4 2024Dec 31, 2024$552.94M+151.0%
Q4 FY2024CQ3 2024Sep 30, 2024$680.96M+68.7%
Q3 FY2024CQ2 2024Jun 30, 2024$436.67M+314.6%
Q2 FY2024CQ1 2024Mar 31, 2024$523.11M+287.6%
Q1 FY2024CQ4 2023Dec 31, 2023$220.28M+8.9%
Q4 FY2023CQ3 2023Sep 30, 2023$403.63M+273.7%
Q3 FY2023CQ2 2023Jun 30, 2023$105.33M-24.5%
Q2 FY2023CQ1 2023Mar 31, 2023$134.96M-35.4%
Q1 FY2023CQ4 2022Dec 31, 2022$202.25M-7.1%
Q4 FY2022CQ3 2022Sep 30, 2022$108.01M-65.3%
Q3 FY2022CQ2 2022Jun 30, 2022$139.44M-69.2%
Q2 FY2022CQ1 2022Mar 31, 2022$208.98M-58.0%
Q1 FY2022CQ4 2021Dec 31, 2021$217.60M-3.7%
Q4 FY2021CQ3 2021Sep 30, 2021$311.16M+36.1%
Q3 FY2021CQ2 2021Jun 30, 2021$452.39M+106.3%
Q2 FY2021CQ1 2021Mar 31, 2021$498.17M+94.1%
Q1 FY2021CQ4 2020Dec 31, 2020$225.93M-51.0%
Q4 FY2020CQ3 2020Sep 30, 2020$228.60M+3.1%
Q3 FY2020CQ2 2020Jun 30, 2020$219.32M+16.5%
Q2 FY2020CQ1 2020Mar 31, 2020$256.65M+58.8%
Q1 FY2020CQ4 2019Dec 31, 2019$461.03M+142.9%
Q4 FY2019CQ3 2019Sep 30, 2019$221.80M+636.1%
Q3 FY2019CQ2 2019Jun 30, 2019$188.33M+572.7%
Q2 FY2019CQ1 2019Mar 31, 2019$161.64M+131.6%
Q1 FY2019CQ4 2018Dec 31, 2018$189.77M+1545.7%
Q4 FY2018CQ3 2018Sep 30, 2018$30.13M+21.3%
Q3 FY2018CQ2 2018Jun 30, 2018$28.00M-27.1%
Q2 FY2018CQ1 2018Mar 31, 2018$69.81M+13.1%
Q1 FY2018CQ4 2017Dec 31, 2017$11.53M-88.7%
Q4 FY2017CQ3 2017Sep 30, 2017$24.84M-70.9%
Q3 FY2017CQ2 2017Jun 30, 2017$38.38M–
Q2 FY2017CQ1 2017Mar 31, 2017$61.72M–
Q1 FY2017CQ4 2016Dec 31, 2016$102.11M–
Q4 FY2016CQ3 2016Sep 30, 2016$85.37M–

More Arrowhead Pharmaceuticals figures

See a number that looks wrong?